- Home
- NTRB vs MIST Comparison
NTRB vs MIST Comparison
Compare NTRB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | MIST |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 163.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NTRB | MIST |
|---|---|---|
| Price | $4.60 | $2.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $8.50 |
| AVG Volume (30 Days) | 23.5K | ★ 9.4M |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.72 | $0.63 |
| 52 Week High | $11.78 | $3.06 |
Technical Indicators
Market Signals| Indicator | NTRB | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 42.49 |
| Support Level | $4.35 | $2.00 |
| Resistance Level | $4.77 | $2.22 |
| Average True Range (ATR) | 0.42 | 0.32 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 19.04 | 37.59 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).